PMA device
MITRIS RESILIA Mitral Valve
Edwards Lifesciences, LLC · Heart-Valve, Non-Allograft Tissue (LWR, Class III) · First FDA decision Mar 16, 2022, newest Mar 1, 2024Aortic stenosisMitral regurgitationTricuspid regurgitation
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
2
Naming "MITRIS RESILIA"
MAUDE reports
266
Brand "MITRIS RESILIA", since 2015
PubMed studies
9
Mentioning "MITRIS RESILIA"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing MITRIS RESILIA Mitral Valve
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- MITRIS RESILIA Mitral ValvePMA supplement
P150048-S079 · Decided Mar 1, 2024 · 24 days after receipt · Normal 180 Day Track No User Fee
Device type: heart-valve, non-allograft tissue (LWR) · Cardiology
- MITRIS RESILIA Mitral ValvePMA supplement
P150048-S047 · Decided Mar 16, 2022 · 590 days after receipt · Normal 180 Day Track
Device type: heart-valve, non-allograft tissue (LWR) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "MITRIS RESILIA", any status and sponsor, newest update first.
- Real-world Clinical Outcomes of the MITRIS RESILIA Mitral ValveActive, not recruiting
Edwards LifesciencesPublic (EW)
NCT05526560 · 504 participants · Start Jan 11, 2023 · Primary completion Jan 2028
Device: MITRIS RESILIA Mitral Valve, Model 11400M · For: Mitral Stenosis; Mitral Valve Insufficiency
Sites: Newport Beach, California; Palo Alto, California; Orlando, Florida · 34 sites in all
Edwards LifesciencesPublic (EW)
NCT07059793 · 250 participants (planned) · Start Jul 8, 2025 · Primary completion Dec 2028
Device: MITRIS RESILIA Mitral Valve · For: Mitral Valve Replacement
Sites: Beijing, China; Xiamen, China; Guangzhou, China · 13 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "MITRIS RESILIA", and for the whole product code for context.
This brand
266 reports: 2 malfunction, 254 injury, 10 death
Whole product code LWR
17,256 reports: 871 malfunction, 15,439 injury, 934 death
Newest reports for this brand
2015691-2026-19695 · Received Oct 26, 2026 · Event dated Sep 28, 2026
Device type: Heart-Valve, Non-Allograft Tissue (LWR)
Device problem as coded: Perivalvular Leak; Patient-Device Incompatibility
Patient problem as coded: Tissue Breakdown
2015691-2026-19662 · Received Oct 23, 2026 · Event dated Sep 8, 2026
Device type: Heart-Valve, Non-Allograft Tissue (LWR)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Insufficient Information
- Edwards Mitris ResiliaInjury
2015691-2026-19308 · Received Oct 12, 2026 · Event dated Sep 8, 2026
Device type: Heart-Valve, Non-Allograft Tissue (LWR)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Insufficient Information
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "MITRIS RESILIA"[tiab]. The summary above synthesizes these.
- Implantability of the MITRIS RESILIA Mitral Valve.
Ushijima T, Kimura S, Shiose A · Ann Thorac Surg · 2022Case Reports
- The Mitris RESILIA Valve: New Skin for a Proven Design.
Ciccarelli G, Weltert L, Scaffa R, et al. · Surg Technol Int · 2024
- Case Series of First Microinvasive Fully Endoscopic Use of a New Mitral Prosthesis.
Kruse J, Silaschi M, Russu K, et al. · J Clin Med · 2024
- Early Haemodynamic Performance and Clinical Outcomes of a Novel Bioprosthetic Mitral Valve.
Wada Y, Marui A, Nagasawa A, et al. · Interdiscip Cardiovasc Thorac Surg · 2025
- Uniformity in bioprosthetic mitral valve sizing-When will we get there?
Tan SZCP, Bashir M, Mohammed I · J Card Surg · 2021
- The MITRIS RESILIA mitral valve is a safe and effective option for mitral valve replacement in young patients requiring mitral valve replacement.
Heye T, Reemtsen B, Greiten L · Cardiol Young · 2023
- [Transprosthetic Cuff Leakage of the MITRIS RESILIA Mitral Valve During Mitral Valve Replacement:Report of a Case].
Imada R, Nagatomi S, Kinjo T, et al. · Kyobu Geka · 2022Case Reports, English Abstract
- Clinical Outcomes of First-Time and Redo Mitral Valve Replacement Using MITRIS RESILIA Bioprosthesis.
Kainuma S, Shimokawa T, Iwakura T, et al. · Ann Thorac Surg Short Rep · 2026
- Early Degeneration of a Next-Generation Mitral Bioprosthesis in the Tricuspid Position Treated With Valve-in-Valve.
Corona S, Mrad S, Ibrahim R, et al. · JACC Case Rep · 2026Case Reports
Other devices of this type
Also filed under product code LWR.
- Edwards Pericardial Aortic Bioprosthesis and INSPIRIS RESILIA Aortic ValveEdwards Lifesciences, LLC · PMA 2022
- St. Jude Medical Biocor and Biocor Supra ValvesAbbott Medical · PMA 2012
- INSPIRIS RESILIA Aortic ValveEdwards Lifesciences, LLC · PMA 2026
- Mitroflow Aortic Pericardial Heart ValveCorcym Canada Corp · PMA 2019
- TRIFORMIS RESILIA Tricuspid ValveEdwards Lifesciences, LLC · PMA 2026
- Perceval Sutureless Heart Valve, Perceval Plus Sutureless Heart ValveCorcym S.r.l. · PMA 2025
- Sjm Biocor Valve / Sjm Biocor Supra ValveAbbott Medical · PMA 2016
- Ats 3F Aortic Bioprosthesis Model 1000Medtronic, Inc. · PMA 2019
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.